Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Effect of dihydroergokryptine administration on serum prolactin and growth hormone levels in normal, hyperprolactinaemic and acromegalic subjects: Evidence of potent and long-lasting pituitary dopamine receptor stimulation

  • 19 Accesses

  • 8 Citations

Summary

The endocrine effects of a relatively potent dopaminergic agent, dihydroergokryptine, have been studied in normal subjects, and in hyperprolactinaemic and acromegalic patients. A single 6 mg oral dose of the drug caused a marked, long lasting fall in prolactin (PRL) plasma levels in healthy subjects, in hyperprolactinaemic patients and in normoprolactinaemic acromegalics. Growth hormone (GH) levels decreased in l-DOPA — responder, acromegalic patients, but dihydroergokryptine did not affect GH levels in normal volunteers or in l-DOPA non — responder, acromegalic patients. The PRL-and GH- lowering activity of 6 mg dihydroergokriptine was significantly greater than that of 6 mg dihydroergocristine, and was similar to that of an oral dose of 500 mg l-DOPA.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Cronin MJ, Roberts JM, Weiner RI (1978) Dopamine and dihydroergokryptine binding to the anterior pituitary and other brain areas of the rat and sheep. Endocrinology 103: 302–309

  2. 2.

    Davis JSN, Strittmatter WNJ, Hoyler E, Lefkowitz RJ (1977) (3H)-dihydroergokryptine binding in rat brain. Brain Res 132: 326–336

  3. 3.

    Tittler M, Weinreich P, Seeman P (1977) New detection of brain dopamine receptors with (3H)-dihydroergokryptine. Proc Natl Acad Sci USA 74: 3750–3753

  4. 4.

    Caron MG, Beaulieu M, Raymond V, Gagné B, Drouin J, Lefkowitz RJ, Labrie F (1978) Dopaminergic receptors in the anterior pituitary gland. Correlation of (3H)-dihydroergokryptine binding with the dopaminergic control of prolactin release. J Biol Chem 253: 2244–2253

  5. 5.

    Libertun C, Larrea GA, Vacas MI, Cardinali DP (1980) (3H)-dihydroergokryptine binding in anterior pituitary and prolactin secretion: further evidence of brain regulation of adenohypophyseal receptors. Endocrinology 107: 1905–1909

  6. 6.

    Fluckiger E, Del Pozo E (1980) Ergot derivatives and pituitary hormones. In: Müller EE (Ed.) Neuroactive drugs in endocrinology. Elsevier/North Holland Biomedical Press, Amsterdam, pp 169–190

  7. 7.

    Poli M, Vitali B, Citella C, Casati R, Platti PM, Monti LD (1983) Effect of different hydrogenated ergot alkaloids on cimetidine-induced prolactin secretion in the normal man. J Endocrinol Invest 6 [Suppl 1]: 32

  8. 8.

    Ferrari C, Romussi M, Benco R, Rampini P, Mailland F (1983) Effect of dihydroergocristine administration on serum prolactin and growth hormone levels in normal, hyperprolactinemic, and acromegalic subjects: further evidence for pituitary dopamine deficiency in these conditions. Acta Endocrinol 103: 1–6

  9. 9.

    Molinatti GM, Massara F, Strumia E, Pennisi F, Scassellati GA, Vancheri L (1969) Radioimmunoassay of GH. J Nucl Biol Med 13: 26–31

  10. 10.

    Sinha AN, Selby FW, Lewis UJ, Vanderlaan WG (1973) A homologous radioimmunoassay for human prolactin. J Clin Endocrinol Metab 36: 500–516

  11. 11.

    Ferrari C, Caldara R, Romussi M, Rampini P, Telloli P, Zaatar S, Curtarelli G (1978) Prolactin suppression by serotonin antagonists in man: further evidence for serotoninergic control of prolactin secretion. Neuroendocrinology 25: 319–328

  12. 12.

    Ferrari C, Caldara R, Rampini P, Telloli P, Romussi M, Bertazzoni A, Polloni G, Mattei A, Crosignani PG (1978) Inhibition of prolactin release by serotonin antagonists in hyperprolactinemic subjects. Metabolism 27: 1499–1504

  13. 13.

    Hunt P, Kannenglesser M, Raynaud J (1974) Nomifensine: a new potent inhibitor of dopamine uptake into synaptosomes from rat brain corpus striatum. J Pharm Pharmacol 26: 370–371

  14. 14.

    Ferrari C, Caldara R, Barbieri C, Testori GP, Benco R, Trezzi R, Crossignani RM, Rampini P (1981) Central nervous system and pituitary mechanisms in dopaminergic stimulation of growth hormone release in women. Neuroendocrinology 32: 213–216

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ferrari, C., Rampini, P., Paracchi, A. et al. Effect of dihydroergokryptine administration on serum prolactin and growth hormone levels in normal, hyperprolactinaemic and acromegalic subjects: Evidence of potent and long-lasting pituitary dopamine receptor stimulation. Eur J Clin Pharmacol 27, 707–711 (1985). https://doi.org/10.1007/BF00547054

Download citation

Key words

  • dihydroergokryptine
  • acromegaly
  • hyperprolactinaemia
  • prolactin
  • growth hormone
  • l-DOPA